Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
March 09, 2023 16:05 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
March 02, 2023 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
December 11, 2022 09:00 ET
|
Aptose Biosciences, Inc.
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to...
Aptose Reports Results for the Third Quarter 2022
November 01, 2022 16:01 ET
|
Aptose Biosciences, Inc.
─ Tuspetinib (HM43239) Dose Escalation and Exploration Phase 1/2 Trial in r/r AML Complete; Continued Superior Safety Profile and Clinical Responses Including Complete Remissions as Single Agent...
Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference
September 14, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
September 13, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability
September 12, 2022 07:30 ET
|
Aptose Biosciences, Inc.
– Initial modeling predicts up to 18-fold improvement in plasma steady-state exposure – – Supports exploration of continuous dosing of G3 formulation – – Lead clinical compound HM43239...
Aptose Reports Results for the Second Quarter 2022
August 02, 2022 16:01 ET
|
Aptose Biosciences, Inc.
─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─ ─ HM43239 Complete Remissions and Safety Across Three Dose Levels...
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
July 27, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
July 19, 2022 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...